Shorla Pharma has been chosen as a finalist for the Reuters Global Pharma Awards in the Most Valuable Breakthrough/Discovery category.
This award is for an original product, product enhancement or scientific invention which has the potential and, ideally, early traction to provide significant impact on a patient population.
There are 35 judges for the Global Pharma Awards, over 800 entries, and just 40 finalists.
Shorla Pharma develop and commercialize innovative oncology drugs for women’s and pediatric cancers. They focus on indications where existing treatments are limited, in shortage or inadequate for the target population.
For more news around the region click here.